多西他赛联合卡培他滨在晚期胃癌中的应用

目的:观察多西他赛联合卡培他滨治疗晚期胃癌的近期疗效及毒副反应。方法:40例晚期胃癌患者接受多西他赛75mg.m-2静脉滴注,第1天;卡培他滨2000mg·m-2,分2次口服,第1~14天;3周为1个周期,治疗3~4个周期后评价疗效及不良反应。结果:在可评价疗效的40例患者中,完全缓解1例(2.5%),部分缓解23例(57.5%),稳定13例(32.5%),进展3例(7.5%),有效率为60.0%。主要不良反应是骨髓抑制、脱发、腹泻、手足综合征。结论:多西他赛联合卡培他滨治疗晚期胃癌具有较好的疗效,不良反应可耐受,是晚期胃癌化疗的有效方案。

Docetaxel in Combination with Xeloda in the Treatment of Advanced Gastric Cancer

OBJECTIVE： To evaluate the efficacy and toxicity of docetaxel plus xeloda in the treatment of advanced gastric cancer, METHODS： Forty patients with advanced gastric cancer were treated with docetaxel 75 mg ·m^-2 on day 1 and xeloda 2 000 mg·m^-2 （in two divided oral doses） for the first 14 days. The chemotherapy repeated every 3 weeks. Efficacy and toxicities were reviewed after 3 to 4 cycles of chemotherapy （1 cycle = 21 days） . RESULTS： Among the 40 evaluable patients, 1 （2.5%） showed complete remission, 23 （57.5%） partial remission, 13 （32.5%） stable and 3 （7.5%） disease progression, and the overall response rate was 60.0% . The main adverse reactions were myelosuppression, alopecia, diarrhea, and hand- foot syndrome. CONCLUSION： The combination of docetaxel and xeloda is well tolerated and effective in the treatment of advanced gastric cancer.